Affiliation:
1. Northern State Medical University; Arkhangelsk Clinical TB Dispensary
2. Arkhangelsk Clinical TB Dispensary
3. Northern State Medical University
Abstract
The objective: to evaluate the efficacy and safety of delamanid in a short-course treatment regimen for patients with MDR/pre-XDR pulmonary tuberculosis in Arkhangelsk Region from 2019 to 2021.Subjects and Methods. 32 patients (4 with MDR TB and 28 with pre-XDR TB) started treatment with delamanid within the combination chemotherapy with new drugs, treatment lasted for 12 months. All patients with pre-XDR TB received delamanid, bedaquiline, linezolid, and clofazimine, then the chemotherapy regimen was compiled depending on the clinical situation.Results. Effective treatment was registered in 21/32 patients (65,6%). 4/32 (12,5%) patients interrupted the treatment. Treatment failure was registered in 2/32 (6,25%). During the study, 5 (15,6%) patients died, in none of them tuberculosis was the cause of death. 106 adverse events (AEs) were reported, they included electrolyte imbalance (18,9%), hepatotoxic (16,0%), nephrotoxic (10,4%) and cardiotoxic (10,4%) reactions.
Publisher
LLC "Medical Knowledge and Technologies"
Reference8 articles.
1. Gayda A. I., Sveshnikova O. M., Verkhovaya V. N., Makhmaeva S. V., Nikishova E. I., Maryandyshev A. O. Treatment of tuberculosis patients with extensive drug resistance using new anti-tuberculosis drugs in the civilian community of Arkhangelsk Region. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 7, pp. 5–10. (In Russ.)
2. Lorsanov S. M., Khaydarkhanova Z. B., Khunkarsultanov S. B. The experience of using delamanid in the Chechen Republic. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 12, pp. 62–63. (In Russ.)
3. Global tuberculosis report 2021. Geneva: World Health Organization; 2021. ISBN 978-92-4-003703-8
4. Maryandyshev A., Lorsanov S., Khaidarkhanova Z., Perkhin D., Sveshnikova O., Gaida A.,.Khimova E, Privolnev V. Delamanid in MDR/XDR pulmonary tuberculosis in Russia: first experience. European Congress of Clinical Microbiology and Infectious Diseases. Abstract book – 30th ECCMID 2020: Abstract 4394.
5. Maryandyshev A., Pontali E., Tiberi S., Akkerman O., Ganatra S., Sadutshang T., et al. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis // Emerg Infect Dis. – 2017. – Vol. 23, № 10. – P. 1718–1721.